Emcure Pharmaceuticals Ltd (EMCURE) is currently trading at 1,515.95 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Emcure Pharmaceuticals Limited develops, manufactures, and markets a wide range of pharmaceutical products across acute and chronic therapeutic areas, including gynecology, cardiovascular, and HIV antivirals. The company's strong financial performance in Q2 FY26 is marked by a 13% year-on-year revenue growth and a 24% increase in profits, showcasing its robust operational capabilities. Emcure has recently entered into a partnership with Novo Nordisk, marking a significant milestone to introduce semaglutide in India, positioning the company in the obesity market early on. Internationally, Emcure is experiencing substantial growth, particularly in Europe and Canada, with the launch of products like Amphotericin B, showing a strategic expansion in global markets. Despite recent debt due to acquisitions, such as completing the purchase of Zuventus, Emcure aims to leverage synergies and maintain strong growth momentum across its diverse portfolio.

Over the past 52 weeks, Emcure Pharmaceuticals Ltd has traded between a low of ₹890.00 and a high of ₹1,585.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Emcure Pharmaceuticals Ltd has a market capitalization of approximately 28,738.25. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Emcure Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 31.76 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Emcure Pharmaceuticals Ltd (EMCURE) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 28,738.25 Cr, Emcure Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Emcure Pharmaceuticals Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Emcure Pharmaceuticals Ltd is 31.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Emcure Pharmaceuticals Ltd pays dividends with a current dividend yield of 0.20%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with Emcure Pharmaceuticals Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.